ロード中...
Design and Synthesis of Type IV Inhibitors of BRAF Kinase that block dimerization and overcome paradoxical MEK/ERK activation
Despite the clinical success of BRAF inhibitors like vemurafenib in treating metastatic melanoma, resistance has emerged through “paradoxical MEK/ERK signaling” where transactivation of one protomer occurs as a result of drug inhibition of the other partner in the activated dimer. The importance of...
保存先:
| 出版年: | J Med Chem |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6750704/ https://ncbi.nlm.nih.gov/pubmed/30977659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.8b01288 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|